Rickets Clinical Trials

Find Rickets Clinical Trials Near You

Study of the Impact of Phosphate Supplementation on FGF23 Concentrations in Patients With Hypophosphatemia

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Fibroblast growth factor 23 (FGF23) is the principal hormone regulating serum phosphate homeostasis. Secreted by osteocytes, it promotes renal phosphate excretion and suppresses the synthesis of 1,25-dihydroxyvitamin D. Measurement of FGF23 has become a key tool in the evaluation of hypophosphatemia, allowing distinction between FGF23-dependent forms (such as X-linked hypophosphatemic rickets, tumor-induced osteomalacia, and intravenous iron-induced hypophosphatemia) and FGF23-independent forms (including renal, gastrointestinal, nutritional, or drug-related causes). In healthy adults, several studies have demonstrated that FGF23 levels vary according to phosphate intake, decreasing during dietary restriction and increasing following phosphate loading. In hypophosphatemic conditions, however, available data are limited to X-linked hypophosphatemic rickets, where prolonged supplementation with phosphate and calcitriol leads to increased FGF23 levels, consistent with the underlying pathophysiology. Based on these observations, it is currently recommended, as a precaution, to measure FGF23 at least 15 days after discontinuation of phosphate supplementation in order to avoid transient elevations that may confound interpretation. In practice, however, this recommendation is difficult to implement, as most patients are already receiving phosphate supplementation at the time of evaluation. To date, no study has specifically assessed the effect of phosphate supplementation in patients with FGF23-independent hypophosphatemia, a condition characterized by appropriately low FGF23 levels. It therefore remains unclear whether supplementation could induce a transient rise in circulating FGF23, potentially leading to misclassification as FGF23-dependent hypophosphatemia (FGF23 \> 95 ng/L). This uncertainty provides a strong rationale for conducting the present study.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patients hospitalized in adult intensive care, oncology, or rheumatology

• Hypophosphatemia \< 0.8 mmol/L

• Clinical indication for phosphate supplementation

Locations
Other Locations
France
CHU Clermont-Ferrand Service de réanimation
RECRUITING
Clermont-ferrand
CHU Clermont-Ferrand Service Oncologie
RECRUITING
Clermont-ferrand
CHU Clermont-Ferrand Service Rhumatologie
RECRUITING
Clermont-ferrand
Contact Information
Primary
Lise Laclautre
promo_interne_drci@chu-clermontferrand.fr
0473754963
Time Frame
Start Date: 2026-06-13
Estimated Completion Date: 2027-09
Participants
Target number of participants: 60
Treatments
Other: Patients hospitalized in adult intensive care, oncology, or rheumatology
Sponsors
Leads: University Hospital, Clermont-Ferrand

This content was sourced from clinicaltrials.gov